Wall Street unfazed by FDA panel’s rejection of company’s wireless heart monitoring device.
|
Boston Scientific’s CFO stands ground that buying troubled heart device maker Boston Scientific was the best thing the company ever did.
|
Year in Review: Innovation and controversy defined the medical technology industry.
|
Medical device maker squirrels away the money to deal with the legal woes of Guidant.
|
Boston Scientific shares dip 7 percent after warnings some devices could cause problems.
|
J&J vows to appeal a judge’s decision that upholds rival company’s heart-device patent.
|
Conor Medsystems implants the first patient with a dual-drug heart device.
|
Medical device maker Guidant gets slapped with a lawsuit over its secrecy policy.
|
Recent recalls stir discussion on the reporting and replacement of faulty cardiac devices.
|
Boston Scientific gets U.S. government clearance to acquire troubled heart device maker Guidant.
|
A U.S. agency’s plan to cut reimbursements for heart devices dents stocks of companies that make them.
|
Firm stirs up the market with a test that could break the hearts of device makers.
|
An independent panel suggests how the troubled heart device maker can better its patient safety communication skills.
|
The problem-plagued company warns doctors about possible battery troubles in some of its defibrillators.
|
Guidant starts the first clinical trial of a heart stent that can be absorbed by the body.
|
Europe probes Boston-Guidant deal; Inamed’s outperforming wrinkle filler; polls shows Americans like techy medicine.
|
Boston Scientific postpones its Guidant acquisition by a week, sacrificing about $31 million in interest.
|
Inspectors say heart device maker failed to report in a timely manner on repair work for certain defibrillator products.
|
BSX 4Q sales slip; Boston Scientific quarterly sales fall; St. Jude pacemakers approved
|
To succeed in the nascent drug-coated stent industry, startups are finding niche markets and cozying up to industry giants.
|
Page
1
of
3
|